# A Randomized, Placebo‐Controlled, Blinded Clinical Trial Evaluating PCSO‐524 as an Adjunctive Therapy for Noninfectious Pododermatitis in Rabbits

## TL;DR

A natural supplement with omega-3 fatty acids (PCSO-524) was tested as an adjunct therapy for noninfectious foot inflammation in rabbits and showed promising results.

## Contribution

This is the first clinical trial to evaluate PCSO-524 as an adjunctive therapy for noninfectious pododermatitis in rabbits.

## Key findings

- PCSO-524 significantly reduced lesion size in rabbits compared to baseline.
- Placebo group showed no significant change in lesion size.
- PCSO-524 was safe with no adverse events reported.

## Abstract

This study evaluated the efficacy and safety of PCSO‐524, a natural supplement containing omega‐3 fatty acids, as an adjunctive therapy for noninfectious pododermatitis (Grades 1‐2) in rabbits. In a randomized, placebo‐controlled, blinded trial, 23 rabbits with noninfectious pododermatitis received either PCSO‐524 or a placebo along with standard treatments for 56 days. PCSO‐524 supplementation led to a statistically significant reduction in the mean lesion size of both hind limbs within the PCSO group compared to baseline (Day 0: 98.55 ± 52.75 mm2, Day 56: 53.18 ± 21.54 mm2; p = 0.002), while the placebo group did not show significant changes (Day 0: 93.98 ± 43.88 mm2, Day 56: 75.61 ± 115.68 mm2; p = 0.58). Both groups exhibited alterations in white blood cell populations (increased monocytes, decreased eosinophils) within normal ranges, and a consistently elevated heterophil‐to‐lymphocyte ratio (HLR; > 1:1). No adverse events were associated with PCSO‐524. This study provides initial evidence for the safety and potential efficacy of a natural supplement containing omega‐3 fatty acids as an adjunctive therapy for noninfectious pododermatitis in rabbits.